21-Gene Recurrence Score and Adjuvant Chemotherapy Decisions in Patients with Invasive Lobular Breast Cancer

References

• Reed AEM , KutasovicJR, LakhaniSR, SimpsonPT. Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics. Breast Cancer Res.17, 12 (2015).
   PubMed Web of Science ®Google Scholar
• García-Fernández A , LainJM, ChabreraCet al. Comparative long-term study of a large series of patients with invasive ductal carcinoma and invasive lobular carcinoma. loco-regional recurrence, metastasis, and survival. Breast J.21 (5), 533–537 (2015).
   PubMed Web of Science ®Google Scholar
• Jayasinghe UW , BilousAM, BoyagesJ. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?Breast J.13 (5), 479–485 (2007).
   PubMed Web of Science ®Google Scholar
• Lim ST , YuJH, ParkHK, MoonBI, KoBK, SuhYJ. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population. World J. Surg. Oncol.12, 56 (2014).
   PubMed Web of Science ®Google Scholar
• Fortunato L , MascaroA, PocciaIet al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period. Ann. Surg. Oncol.19 (4), 1107–1114 (2012).
   PubMed Web of Science ®Google Scholar
• Rakha EA , EllisIO. Lobular breast carcinoma and its variants. Semin. Diagn. Pathol.27 (1), 49–61 (2010).
   PubMed Web of Science ®Google Scholar
• Loibl S , VolzC, MauCet al. Response and prognosis after neoadjuvant chemotherapy in 1051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res. Treat.144 (1), 153–162 (2014).
   PubMed Web of Science ®Google Scholar
• Delpech Y , CoutantC, HsuLet al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br. J. Cancer108 (2), 285–291 (2013).
   PubMed Web of Science ®Google Scholar
• Marmor S , HuiJYC, HuangJLet al. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer123 (16), 3015–3021 (2017).
   PubMed Web of Science ®Google Scholar
• Vieira AF , SchmittF. An update on breast cancer multigene prognostic tests-emergent clinical biomarkers. Front. Med (Lausanne)5, 248 (2018).
   PubMed Web of Science ®Google Scholar
• Paik S , ShakS, TangGet al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351 (27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Sparano JA , GrayRJ, MakowerDFet al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med.379 (2), 111–121 (2018).
   PubMed Web of Science ®Google Scholar
• Krop I , IsmailaN, AndreFet al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol.35 (24), 2838–2847 (2017).
   PubMed Web of Science ®Google Scholar
• Surveillance, epidemiology, and end results (SEER) program. SEER*Stat Database: Incidence – SEER 18 Regs (Excl AK) custom data malignant breast (with Oncotype DX and additional treatment fields), Nov 2017 sub (2004–2015) – linked to county attributes – total US, 1969–2016 counties, national cancer institute, DCCPS, surveillance research program, released April 2018, based on the November 2017 submission. www.seer.cancer.gov.
   Google Scholar
• Wong WB , RamseySD, BarlowWE, GarrisonLPJr, VeenstraDL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp. Clin. Trials33 (6), 1117–1123 (2012).
   PubMed Web of Science ®Google Scholar
• Noone AM , LundJL, MariottoAet al. Comparison of SEER treatment data with medicare claims. Med. Care54 (9), e55–64 (2016).
   PubMed Web of Science ®Google Scholar
• Albanell J , SvedmanC, GligorovJet al. Pooled analysis of prospective European studies assessing the impact of using the 21-gene recurrence score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Eur. J. Cancer66, 104–113 (2016).
   PubMed Web of Science ®Google Scholar
• Barcenas CH , RaghavendraA, SinhaAKet al. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer123 (13), 2422–2431 (2017).
   PubMed Web of Science ®Google Scholar
• Stemmer SM , SteinerM, RizelSet al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer3, 33 (2017).
   PubMed Web of Science ®Google Scholar
• Kelly CM , KrishnamurthyS, BianchiniGet al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer116 (22), 5161–5167 (2010).
   PubMed Web of Science ®Google Scholar
• Conlon N , RossDS, HowardJ, CatalanoJP, DicklerMN, TanLK. Is there a role for Oncotype Dx testing in invasive lobular carcinoma?Breast J.21 (5), 514–519 (2015).
   PubMed Web of Science ®Google Scholar
• Felts JL , ZhuJ, HanB, SmithSJ, TruicaCI. An analysis of Oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J.23 (6), 677–686 (2017).
   PubMed Web of Science ®Google Scholar
• Tsai ML , LillemoeTJ, FinkelsteinMJet al. Utility of Oncotype DX risk assessment in patients with invasive lobular carcinoma. Clin. Breast Cancer16 (1), 45–50 (2016).
   PubMed Web of Science ®Google Scholar
• Kizy S , HuangJL, MarmorSet al. Distribution of 21-gene recurrence scores among breast cancer histologic subtypes. Arch. Pathol. Lab. Med.142 (6), 735–741 (2018).
   PubMed Web of Science ®Google Scholar
• Rakha EA , El-SayedME, MenonS, GreenAR, LeeAH, EllisIO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res. Treat.111 (1), 121–127 (2008).
   PubMed Web of Science ®Google Scholar
• Carbognin L , SperdutiI, FabiAet al. Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: cut-off analysis of Ki67 according to histology and clinical validation. Breast35, 21–26 (2017).
   PubMed Web of Science ®Google Scholar
• Senkus E , KyriakidesS, OhnoSet al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26 (Suppl. 5), v8–30 (2015).
   PubMed Web of Science ®Google Scholar
• Curigliano G , BursteinHJ, WinerEPet al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann. Oncol.29 (10), 2153 (2018).
   PubMed Web of Science ®Google Scholar
• Kizy S , HuangJL, MarmorS, TuttleTM, HuiJYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res. Treat.165 (3), 757–763 (2017).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC , ZahriehD, MallonEet al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J. Clin. Oncol.26 (18), 3006–3014 (2008).
   PubMed Web of Science ®Google Scholar
• Rakha EA , El-SayedME, PoweDGet al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur. J. Cancer44 (1), 73–83 (2008).
   PubMed Web of Science ®Google Scholar
• Truin W , VoogdAC, VreugdenhilG, van der Heiden-van der LooM, SieslingS, RoumenRM. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann. Oncol.23 (11), 2859–2865 (2012).
   PubMed Web of Science ®Google Scholar
• Truin W , VugtsG, RoumenRMet al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann. Surg. Oncol.23 (1), 51–57 (2016).
   PubMed Web of Science ®Google Scholar
• Katz A , SaadED, PorterP, PusztaiL. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol.8 (1), 55–62 (2007).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M , Gonzalez-AnguloA, SneigeNet al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J. Clin. Oncol.23 (1), 41–48 (2005).
   PubMed Web of Science ®Google Scholar